Search Results - "FOSTER, R. S"

Outcome analysis of patients with transformed teratoma to primitive neuroectodermal tumor by Ehrlich, Y., Beck, S.D.W., Ulbright, T.M., Cheng, L., Brames, M.J., Andreoiu, M., Foster, R.S., Einhorn, L.H.

“…The emergence of a primitive neuroectodermal tumor (PNET) within a germ-cell tumor (GCT) is rare. We assess the prognosis and response to treatment. Eighty-one…”
Get full text

Collagen remodelling by airway smooth muscle is resistant to steroids and β2-agonists by BOURKE, J. E, LI, X, FOSTER, S. R, WEE, E, DAGHER, H, ZIOGAS, J, HARRIS, T, BONACCI, J. V, STEWART, A. G

“…Bi-directional interactions between airway smooth muscle (ASM) and the altered extracellular matrix (ECM) may influence airway wall remodelling and ASM…”
Get full text

American Cancer Society Guidelines for Breast Cancer Screening: Update 2003 by Smith, Robert A, Saslow, Debbie, Andrews Sawyer, Kimberly, Burke, Wylie, Costanza, Mary E, Evans, W. Phil, III, Foster, Roger S., Jr, Hendrick, Edward, Eyre, Harmon J, Sener, Steven

“…In 2003, the American Cancer Society updated its guidelines for early detection of breast cancer based on recommendations from a formal review of evidence and…”
Get full text

Molecular genetic evidence supporting the neoplastic nature of stromal cells in 'fibrosis' after chemotherapy for testicular germ cell tumours by Cheng, L, Zhang, S, Wang, M, Davidson, DD, Morton, MJ, Huang, J, Zheng, S, Jones, TD, Beck, SD, Foster, RS

“…A residual retroperitoneal mass containing only fibrosis and necrosis is present in 40-52% of patients with advanced testicular germ cell tumours after…”
Get full text

Late relapse of testicular cancer by Baniel, J, Foster, R S, Gonin, R, Messemer, J E, Donohue, J P, Einhorn, L H

“…This study analyzed a large group of patients with testicular germ cell cancer in complete remission, who relapsed more than 2 years after completion of…”
Get more information

Commentary on “Prognostic effect of carcinoma in situ in muscle-invasive urothelial carcinoma patients receiving neoadjuvant chemotherapy.” by Thomas, DE, Kaimakliotis, HZ, Rice, KR, Pereira, JA, Johnston, P, Moore, ML, Reed, A, Cregar, DM, Franklin, C, Loman, RL, Koch, MO, Bihrle, R, Foster, RS, Masterson, TA, Gardner, TA, Sundaram, CP, Powell, CR, Beck, SDW, Grignon, DJ, Cheng, L, Albany, C, Hahn, NM

“…Carcinoma in situ (CIS) is a poor prognostic finding in urothelial carcinoma. However, its significance in muscle-invasive urothelial carcinoma (MIUC) treated…”
Get full text

Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors by Albany, C., Adra, N., Snavely, A.C., Cary, C., Masterson, T.A., Foster, R.S., Kesler, K., Ulbright, T.M., Cheng, L., Chovanec, M., Taza, F., Ku, K., Brames, M.J., Hanna, N.H., Einhorn, L.H.

“…To report our experience utilizing a multidisciplinary clinic (MDC) at Indiana University (IU) since the publication of the International Germ Cell Cancer…”
Get full text

Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder by MOHAMMED, S. I, KNAPP, D. W, BOSTWICK, D. G, FOSTER, R. S, KHAN, K. N. M, MASFERRER, J. L, WOERNER, B. M, SNYDER, P. W, KOKI, A. T

“…Cyclooxygenase (COX)-inhibiting drugs have antitumor activity in canine and rodent models of urinary bladder cancer. Two isoenzymes of COX have been…”
Get full text

Regulation of the β -Adrenergic Receptor Signaling Pathway in Sustained Ligand-Activated Preconditioning by See Hoe, L E, Foster, S R, Wendt, L, Patel, H H, Headrick, J P, Peart, J N

“…Sustained ligand-activated preconditioning (SLP), induced with chronic opioid receptor (OR) agonism, enhances tolerance to ischemia/reperfusion injury in young…”
Get more information

Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation by Donohue, J P, Thornhill, J A, Foster, R S, Rowland, R G, Bihrle, R

“…Results with primary retroperitoneal lymphadenectomy in 464 patients with clinical stage A nonseminomatous germ cell testis cancer (1965 to 1989) were…”
Get more information

The pathology of late recurrence of testicular germ cell tumors by MICHAEL, H, LUCIA, J, FOSTER, R. S, ULBRIGHT, T. M

“…A total of 91 men had histologically documented late recurrences of testicular germ cell tumors characterized by a complete response to treatment with a…”
Get full text

Complications of primary retroperitoneal lymph node dissection by Baniel, J, Foster, R S, Rowland, R G, Bihrle, R, Donohue, J P

“…The surgical morbidity in 478 patients who underwent primary retroperitoneal lymphadenectomy for clinical stages I and II nonseminomatous testicular cancer…”
Get more information

What are the indications for postchemotherapy retroperitoneal lymph node dissection? by Einhorn, L.H., Foster, R.S.

“…Postchemotherapy retroperitoneal lymph node dissection (RPLND) is routinely performed if there is persistent >1 cm adenopathy. Some centers also recommend…”
Get full text

Giant Pulses from the Crab Pulsar: A Joint Radio and Gamma-Ray Study by Lundgren, S. C., Cordes, J. M., Ulmer, M., Matz, S. M., Lomatch, S., Foster, R. S., Hankins, T.

Get full text

Results and Outcome of Retroperitoneal Lymph Node Dissection for Clinical Stage I Embryonal Carcinoma–Predominant Testis Cancer by SWEENEY, C. J, HERMANS, B. P, HEILMAN, D. K, FOSTER, R. S, DONOHUE, J. P, EINHORN, L. H

“…To determine the incidence of metastatic disease and usage of chemotherapy (adjuvant or metastatic) after primary retroperitoneal lymph node dissection (RPLND)…”
Get full text

Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection by Hermans, B P, Sweeney, C J, Foster, R S, Einhorn, L E, Donohue, J P

“…We assess the risk of systemic recurrence after retroperitoneal lymph node dissection for clinical stage I nonseminoma germ cell testis tumor based on…”
Get more information

Evaluation of QSAR models for predicting mutagenicity: outcome of the Second Ames/QSAR international challenge project by Furuhama, A., Kitazawa, A., Yao, J., Matos dos Santos, C.E., Rathman, J., Yang, C., Ribeiro, J.V., Cross, K., Myatt, G., Raitano, G., Benfenati, E., Jeliazkova, N., Saiakhov, R., Chakravarti, S., Foster, R.S., Bossa, C., Battistelli, C. Laura, Benigni, R., Sawada, T., Wasada, H., Hashimoto, T., Wu, M., Barzilay, R., Daga, P.R., Clark, R.D., Mestres, J., Montero, A., Gregori-Puigjané, E., Petkov, P., Ivanova, H., Mekenyan, O., Matthews, S., Guan, D., Spicer, J., Lui, R., Uesawa, Y., Kurosaki, K., Matsuzaka, Y., Sasaki, S., Cronin, M.T.D., Belfield, S.J., Firman, J.W., Spînu, N., Qiu, M., Keca, J.M., Gini, G., Li, T., Tong, W., Hong, H., Liu, Z., Igarashi, Y., Yamada, H., Sugiyama, K.-I., Honma, M.

“…Quantitative structure−activity relationship (QSAR) models are powerful in silico tools for predicting the mutagenicity of unstable compounds, impurities and…”
Get full text

EGRET Observations of the Gamma-Ray Source 2CG 135+01 by Kniffen, D. A, Alberts, W. C. K, Bertsch, D. L, Dingus, B. L, Esposito, J. A, Fichtel, C. E, Foster, R. S, Hartman, R. C, Hunter, S. D, Kanbach, G, Lin, Y. C, Mattox, J. R, Mayer-Hasselwander, H. A, Michelson, P. F, von Montigny, C, Mukherjee, R, Nolan, P. L, Paredes, J. M, Ray, P. S, Schneid, E. J, Sreekumar, P, Tavani, M, Thompson, D. J

Get full text

High intensity focused ultrasound for the treatment of benign prostatic hyperplasia: early United States clinical experience by Bihrle, R, Foster, R S, Sanghvi, N T, Donohue, J P, Hood, P J

“…High intensity focused ultrasound via a transrectal approach was used to treat 15 patients with symptomatic benign prostatic hyperplasia. The first 10 of these…”
Get more information

Identification of clinical stage A nonseminomatous testis cancer patients at extremely low risk for metastatic disease: a combined approach using quantitive immunohistochemical, histopathologic, and radiologic assessment by Leibovitch, I, Foster, R S, Kopecky, K K, Albers, P, Ulbright, T M, Donohue, J P

“…To evaluate previously determined predictors of metastasis in low-stage testis cancer in a consecutive group of clinical stage A patients. Ninety-one…”
Get more information